4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
12.25
+1.00 (8.89%)
Nov 6, 2026, 4:00 PM EST - Market closed
4D Molecular Therapeutics Employees
4D Molecular Therapeutics had 196 employees as of December 31, 2025. The number of employees decreased by 31 or 13.66% compared to the previous year. That makes 4D Molecular Therapeutics the 26,960th largest employer in the world and 3,400th in the United States.
Employees
196
Change (1Y)
-31
Growth (1Y)
-13.66%
Revenue / Employee
$469,429
Profits / Employee
-$914,158
Market Cap
676.74M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 196 | -31 | -13.66% |
| Dec 31, 2024 | 227 | 80 | 54.42% |
| Jun 30, 2024 | 201 | 64 | 46.72% |
| Mar 31, 2024 | 171 | 34 | 24.82% |
| Dec 31, 2023 | 147 | 7 | 5.00% |
| Sep 30, 2023 | 144 | 4 | 2.86% |
| Jun 30, 2023 | 137 | -1 | -0.72% |
| Mar 31, 2023 | 137 | 0 | - |
| Dec 31, 2022 | 140 | 16 | 12.90% |
| Sep 30, 2022 | 140 | 19 | 15.70% |
| Jun 30, 2022 | 138 | 34 | 32.69% |
| Mar 31, 2022 | 137 | 49 | 55.68% |
| Dec 31, 2021 | 124 | 41 | 49.40% |
| Sep 30, 2021 | 121 | 43 | 55.13% |
| Jun 30, 2021 | 104 | 26 | 33.33% |
| Mar 31, 2021 | 88 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Wave Life Sciences | 317 |
| Aura Biosciences | 113 |
| Adlai Nortye Group | 109 |
| Helus Pharma | 100 |
| ArriVent BioPharma | 77 |
| Zevra Therapeutics | 61 |
| Candel Therapeutics | 55 |
| Achieve Life Sciences | 28 |
FDMT News
- 5 days ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 18 days ago - 4D Molecular Therapeutics Transcript: Investor Day 2026 - Transcripts
- 18 days ago - 4D Molecular Therapeutics Slides: FY 2026 - Filings
- 23 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 4 weeks ago - 4DMT to Host Investor Day on October 21, 2026 - GlobeNewsWire
- 5 weeks ago - 4D Molecular price target raised to $33 from $29 at BofA - TheFly
- 5 weeks ago - Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results - TheFly
- 5 weeks ago - 4D Molecular announces first patients enrolled in 4SIGHT Phase 3 trial - TheFly